DRD5

D(1B) dopamine receptor · P21918 · DRD5 on Sugi Atlas →

73,615 patent compounds predicted against DRD5, 47,512 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL164206	0.85	13/20
Hydrochloric Acid (SCHEMBL165521)	0.81	13/20
Sulfuric Acid (SCHEMBL174314)	0.65	12/20
Succinic Acid (SCHEMBL170445)	0.64	12/20
SCHEMBL93622	0.56	10/20
SCHEMBL215877	0.55	10/20
SCHEMBL98108	0.74	9/20
SCHEMBL160943	0.55	9/20
Setiptiline (SCHEMBL211362)	0.60	8/20
SCHEMBL227363	0.59	8/20
Maleic Acid (SCHEMBL167958)	0.59	8/20
SCHEMBL43307	0.53	8/20
Orotic Acid (SCHEMBL163210)	0.44	8/20
Adipic Acid (SCHEMBL166309)	0.60	7/20
SCHEMBL217399	0.53	7/20
SCHEMBL218317	0.53	7/20
SCHEMBL216418	0.50	7/20
Nitric Acid (SCHEMBL165780)	0.47	7/20
Benproperine (SCHEMBL142207)	0.58	6/20
SCHEMBL225156	0.46	6/20

Clinical trials — most relevant to DRD5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD	PHASE4	UNKNOWN
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder	PHASE4	UNKNOWN
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)	PHASE4	COMPLETED
Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)	PHASE4	COMPLETED
New Treatment for Alcohol and Nicotine Dependence	PHASE2/PHASE3	COMPLETED
Psychopharmacology for Cocaine Dependence - Buspirone	PHASE2	COMPLETED
Modafinil vs Placebo for the Treatment of Methamphetamine Dependence	PHASE2	COMPLETED
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112	PHASE1	COMPLETED
The Association Between Executive Functions and Candidate Genes of Dopaminergic and Noradrenergic Systems in Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
Attention Deficit Hyperactivity Disorder: Nutrition and Environment	nan	UNKNOWN
Endophenotype, Molecular Genetic Study on Attention-Deficit/Hyperactivity Disorder	nan	COMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Molecular Genetic Study of Schizophrenia: Parent-Offspring Trios	nan	COMPLETED
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder	nan	COMPLETED
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality	nan	SUSPENDED
An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD	nan	COMPLETED
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
The Genetic Basis for Vulnerability to Substance Abuse	nan	COMPLETED
Practice Based Nutrition Intervention-2	nan	COMPLETED
Individual Differences in Reward and Impulse Control	nan	COMPLETED
Pilot Study on Caffeine Efficiency in ADCY5-related Dyskinesia	nan	COMPLETED
Dopamine and Insulin Resistance	nan	COMPLETED
Assessment of ADCY5-related Movement Disorders With Motion SENSors	nan	COMPLETED
Molecular Epidemiology of Parkinson's Disease	nan	COMPLETED
Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain	nan	ENROLLING_BY_INVITATION
Genetics of Self-injurious Behaviour	nan	COMPLETED
Caffeine Efficacy in ADCY5-related Dyskinesia	nan	UNKNOWN
Endophenotyping With Functional Magnetic Resonance Imaging (fMRI)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DRD5 binder may also engage these)

Protein	Name	Similarity
P25115	—	1.000	P25115 →
P18901	—	1.000	P18901 →
Q8BLD9	—	0.997	Q8BLD9 →
P50130	—	0.996	P50130 →
P42288	—	0.996	P42288 →
Q95136	—	0.996	Q95136 →
DRD1	D(1A) dopamine receptor	0.994	landscape →
Q91175	—	0.994	Q91175 →
P54833	—	0.994	P54833 →
Q16950	—	0.994	Q16950 →
P53454	—	0.993	P53454 →
DRD2	D(2) dopamine receptor	0.993	landscape →
Q5IS72	—	0.993	Q5IS72 →
P42290	—	0.992	P42290 →
Q6XXX9	—	0.992	Q6XXX9 →
P10608	—	0.992	P10608 →
P19020	—	0.992	P19020 →
P60026	—	0.992	P60026 →
Q25321	—	0.991	Q25321 →
Q25322	—	0.991	Q25322 →
Q91081	—	0.991	Q91081 →
P04274	—	0.991	P04274 →
Q4KWL2	—	0.991	Q4KWL2 →
P52702	—	0.991	P52702 →
O42384	—	0.991	O42384 →
HTR4	5-hydroxytryptamine receptor 4	0.991	landscape →
Q6XXY0	—	0.991	Q6XXY0 →
P52703	—	0.991	P52703 →
Q61616	—	0.991	Q61616 →
O77680	—	0.990	O77680 →